Haleon, the consumer healthcare company behind brands like Sensodyne and Centrum, saw its stock price plummet 5.05% in intraday trading on Thursday. This sharp decline came after the company's revenue growth forecast for 2025 fell short of analysts' expectations.
According to Haleon's guidance, the company expects organic revenue growth of 4% to 6% for the year 2025, lower than the consensus estimate of 5.3%. While the company reported solid fourth-quarter results and full-year revenue of £11.23 billion, in line with expectations, investors seemed concerned about the potential slowdown in growth.
Analysts at Jefferies acknowledged the strong fourth-quarter sales but noted that the company's "broad outlook commitment" overshadowed these positive results. They described Haleon's forecast as "wise" given the ongoing uncertainties, but it appears that the market had higher expectations for the company's revenue growth trajectory.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.